Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Sees Significant Increase in Short Interest

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a large growth in short interest in June. As of June 15th, there was short interest totaling 22,107 shares, a growth of 575.0% from the May 31st total of 3,275 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 263,781 shares, the short-interest ratio is currently 0.1 days.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BRNS. Baird Financial Group Inc. raised its position in Barinthus Biotherapeutics by 108.2% during the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock valued at $179,000 after purchasing an additional 100,000 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Barinthus Biotherapeutics by 115.8% in the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after purchasing an additional 76,800 shares in the last quarter. Finally, Rangeley Capital LLC increased its position in shares of Barinthus Biotherapeutics by 88.8% during the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after purchasing an additional 75,024 shares during the last quarter. Institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Stock Down 2.6%

Shares of BRNS stock traded down $0.02 during trading on Friday, hitting $0.70. The company had a trading volume of 6,869 shares, compared to its average volume of 156,395. The stock’s 50-day moving average is $0.67 and its two-hundred day moving average is $0.66. The stock has a market capitalization of $28.59 million, a price-to-earnings ratio of -0.54 and a beta of -0.40. Barinthus Biotherapeutics has a 52 week low of $0.51 and a 52 week high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.14.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $4.00.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.